BioStem Technologies (BSEM) vs Dyadic International (DYAI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Dyadic International (DYAI) has outperformed BioStem Technologies (BSEM) over the past year, losing 68.8% versus a loss of 84.0%. Over five years, BSEM leads with a -55.9% price change compared with -92.2% for DYAI. BioStem Technologies is the larger company by market cap ($12.2 million vs $11.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BSEM | DYAI |
|---|---|---|
| Share price | $0.6351 | $0.287 |
| Market cap | $12.18M | $11.51M |
| 1-day change | -10.23% | -7.66% |
| YTD return | -83.33% | -69.47% |
| 1-year return | -83.98% | -68.80% |
| 5-year return | -55.90% | -92.24% |
| P/E ratio (TTM) | 0.72 | — |
| Forward P/E | 2.19 | — |
| EPS (TTM) | $0.88 | $-0.21 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $3.09M |
| Revenue growth (YoY) | — | -11.59% |
| Net income (latest FY) | — | $-7.36M |
| Gross margin | — | 24.93% |
| Operating margin | — | -232.75% |
| Net margin | — | -238.31% |
| 52-week high | $8.40 | $1.60 |
| 52-week low | $0.5347 | $0.285 |
| Distance from 52-week high | -92.44% | -82.06% |
| Analyst consensus | none | none |
| Avg. price target upside | +1002.19% | +1816.38% |
| Average volume | 194.93K | 140.81K |
| Shares outstanding | 19.18M | 40.09M |
| Employees | 73 | 5 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DYAI has outperformed BSEM by 15.2 percentage points over the past year.
About BioStem Technologies
BSEM stock →BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 73 employees
About Dyadic International
DYAI stock →Dyadic International, Inc., together with its subsidiaries, a biotechnology platform company, develops, manufactures, and commercializes proteins and enzymes in the United States. The company offers Dapibus Protein Production Platform, a proprietary expression system designed to produce non-animal proteins and enzymes for non-pharmaceutical markets, including life sciences, food and nutrition, and bio-industrial sector; and C1 Protein Production Platform, a thermophilic fungal platform for large-scale production of proteins.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 5 employees
BSEM vs DYAI FAQ
Which is bigger, BioStem Technologies or Dyadic International?
BioStem Technologies (BSEM) is larger, with a market capitalization of $12.18M compared with $11.51M for Dyadic International (DYAI).
Which stock has performed better over the past year, BSEM or DYAI?
DYAI returned -68.80% over the past 12 months, compared with -83.98% for BSEM (price return, excluding dividends). Past performance does not predict future results.
Are BioStem Technologies and Dyadic International in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.